Following a European Medicines Agency recommendation in March, the European Commission has now granted formal approval for Carvykti (ciltacabtagene autoleucel, or cilta-cel), from Johnson & Johnson’s (NYSE: JNJ) subsidiary Janssen
The chimeric antigen receptor T-cell (CAR-T) drug is cleared for the treatment of adults with heavily pre-treated relapsed and refractory multiple myeloma. This marks the first approval of this therapy outside of the USA, where it as approved by the Food and Drug Administration for the same indication in March this year.
What this means for patients and the medical community:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze